The EpiVacCorona coronavirus vaccine, developed by the Vector Research Center, has undergone clinical trials and is registered for use in Russia. This was announced today by Russian President Vladimir Putin.
“I would like to start with something else, with the pleasant information that the Novosibirsk center“ Vector ”has registered the second Russian vaccine against coronavirus today,” Vladimir Putin said today, opening a meeting with members of the government.
We are talking about the drug “EpiVacCorona” vector action. According to Rospotrebnadzor, the vaccine has successfully passed clinical trials with volunteers, no unwanted side effects have been identified. On the eve of Deputy Prime Minister Tatyana Golikova announced that post-registration clinical trials will take place in the regions of Russia with the participation of 40 thousand volunteers, including those over 60. The first batches of EpiVacCorona – 60 thousand doses – will be produced in the near future.
Recall that the first registered Russian vaccine against coronavirus “Sputnik V” was created by the Center. Gamalei together with the Ministry of Defense. The production of the drug was launched on August 15, mass vaccination is planned in 2021.